GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

After months of rumous, Audi has unveiled a new EV range in China, sporting, instead of the rings (arguably one of the best ...

And that earns it the top spot in our round of the best logo maker and designer tools. As such, this makes Wix the best logo maker for beginners (or creatives in a hurry). You can change colors ...

The release of these new data highlights AREXVY’s potential to significantly reduce the burden of RSV in older populations, ...

GSK Earnings: Solid Growth Led by New RSV Vaccine Arexvy GSK reported strong third-quarter results slightly ahead of our expectations, largely driven by excellent sales of RSV vaccine Arexvy.

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

New data for Arexvy, GSK's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease · Single dose of vaccine elicited robust ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger performance. Drugmaker GSK saw a sharp drop in revenue from its blockbuster ...